Loss of CD55 in Eculizumab-Responsive Protein-Losing Enteropathy

N Engl J Med. 2017 Jul 6;377(1):87-89. doi: 10.1056/NEJMc1707173. Epub 2017 Jun 28.

Authors

Alina Kurolap¹, Orly Eshach-Adiv², Tova Hershkovitz², Tamar Paperna², Adi Mory², Danit Oz-Levi², Yaniv Zohar², Hanna Mandel², Judith Chezar³, David Azoulay³, Sarit Peleg⁴, Elizabeth E Half², Vered Yahalom⁵, Lilach Finkel⁵, Omer Weissbrod¹, Dan Geiger¹, Adi Tabib⁶, Ron Shaoul², Daniella Magen², Lilach Bonstein², Dror Mevorach⁶, Hagit N Baris⁷

Affiliations

¹ Technion-Israel Institute of Technology, Haifa, Israel.
² Rambam Health Care Campus, Haifa, Israel.
³ Western Galilee Hospital, Nahariya, Israel.
⁴ HaEmek Medical Center, Afula, Israel.
⁵ Magen David Adom National Blood Services, Ramat Gan, Israel.
⁶ Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
⁷ Rambam Health Care Campus, Haifa, Israel hb_feldman@rambam.health.gov.il.

PMID: 28657861
DOI: 10.1056/NEJMc1707173

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use*
CD55 Antigens / genetics*
Child
Child, Preschool
Compassionate Use Trials
Complement Activation
Complement Membrane Attack Complex / metabolism
Diarrhea / etiology
Female
Frameshift Mutation*
Humans
Male
Middle Aged
Pedigree
Protein-Losing Enteropathies / drug therapy*
Protein-Losing Enteropathies / genetics*
Sequence Analysis, DNA
Serum Albumin / metabolism
Young Adult

Substances

Antibodies, Monoclonal, Humanized
CD55 Antigens
Complement Membrane Attack Complex
Serum Albumin
eculizumab